| __timestamp | Gilead Sciences, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 10337679 |
| Thursday, January 1, 2015 | 3426000000 | 18187286 |
| Friday, January 1, 2016 | 3398000000 | 24758063 |
| Sunday, January 1, 2017 | 3878000000 | 23666957 |
| Monday, January 1, 2018 | 4056000000 | 30099855 |
| Tuesday, January 1, 2019 | 4381000000 | 64947625 |
| Wednesday, January 1, 2020 | 5151000000 | 186363444 |
| Friday, January 1, 2021 | 5246000000 | 272611040 |
| Saturday, January 1, 2022 | 5673000000 | 358782000 |
| Sunday, January 1, 2023 | 6090000000 | 409864000 |
| Monday, January 1, 2024 | 6091000000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc. have demonstrated contrasting approaches to SG&A cost management.
From 2014 to 2023, Gilead Sciences saw a steady increase in SG&A expenses, rising by approximately 104%, from $2.98 billion to $6.09 billion. This reflects their expansive growth strategy and investment in administrative capabilities. In contrast, Intra-Cellular Therapies, while starting with significantly lower SG&A costs, experienced a dramatic increase of nearly 3,900%, from $10.34 million to $409.86 million. This surge highlights their aggressive scaling efforts in a competitive market.
Understanding these trends provides valuable insights into how these companies balance growth with operational efficiency, offering lessons for investors and industry analysts alike.
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated
Gilead Sciences, Inc. vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared